New NASDAQ Alert [Inside]

AwesomeStocks Hello! We have a new high volatility alert that we wanted to bring to your attention today. New Alert: Bionomics Limited (NASDAQ: BNOX) BNOX has been trending higher over the past few days and has experienced some increased upside volatility. On Tuesday, BNOX rallied above its 20 day moving average, afterwards breaking to a high of 7.71. BNOX experienced gains of more than 132% that day. Since then, it has consolidated back under its 20 day moving average of 3.62. A breakout above the 20 and 50 day moving averages could once again present increased upside potential. BNOX has a 200 day moving average of 6.50, more than 89% above yesterday’s close presenting increased upside potential. In addition, BNOX is one of the companies that is solving a growing global problem. Anxiety disorders are the most common and pervasive mental disorders in the United States. These disorders affect the way a person thinks, feels, behaves, and functions. It's a normal part of life to experience occasional anxiety. However, many people experience anxiety that is persistent, seemingly uncontrollable, and overwhelming to the point where it interferes with daily activities. Sadly, “It's not uncommon for someone with an anxiety disorder to also suffer from depression or vice versa. Nearly one-half of those diagnosed with depression are also diagnosed with an anxiety disorder.” According to the ADAA, “anxiety disorders are the most common mental illness in the U.S., affecting 40 million adults (19.1% of the population) age 18 and older every year.” Social Anxiety Disorder, sometimes called social phobia, is an “anxiety disorder characterized by extreme fear or anxiety in one or more social settings”. According to the NIH, an “estimated 7.1% of U.S. adults had social anxiety disorder in the past year”. BNOX, our new breakout alert, is one of the companies that could provide a solution to this growing problem. BNOX is a “clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious CNS disorders with high unmet medical need”. BNOX is “developing treatments for patients with underserved” “Central Nervous System (“CNS”) disorders”. BNOX is “advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD)”. As the company further explains: “Formulated as an oral solid tablet BNC210 is a negative allosteric modulator of the α7 nicotinic acetylcholine receptor under development for the treatment of SAD and Post-Traumatic Stress Disorder (PTSD).” Importantly: “BNC210 has been given FDA Fast Track designation for acute treatment of SAD and other anxiety related disorders, and for treatment of PTSD and other trauma and stressor related disorders.” In addition: BNOX “has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions”. BNOX has announced multiple accomplishments recently. In December, the company announced: “Bionomics appoints Spyridon “Spyros” Papapetropoulos as President and Chief Executive Officer” - “Experienced biotech executive to lead the next phase of growth” Here are some of the comments from this press release: “Dr. De Souza commented “Bionomics is at a key inflection point in its development and potential transition from an early-stage development organization to a later stage clinical development and commercial organization as we await the data from our two ongoing Phase 2 clinical trials of BNC210 for the acute treatment of social anxiety disorder and chronic treatment of post-traumatic stress disorder by year end 2022 and mid-2023, respectively. Having led the Company turn around over the past three years, I am delighted to hand over the reins to Spyros to leverage his extensive experience in leading R&D and commercial organizations in both the private and public sector and small biotech and large pharmaceutical companies to continue to progress the pipeline and in doing so, build value for patients and shareholders. I will continue to be closely involved with Bionomics in my oversight role as Non-Executive Chairman of the Board.”” In addition, the company also announced: “Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety Disorder” Here are some of the highlights from this press release: - “BNC210 for Treatment of Social Anxiety Disorder (SAD) Did Not Meet Primary Endpoint” - “Subjects with Confirmed SAD who Received BNC210 Exhibited Trends Toward Improvements Across Endpoints Compared to Placebo” - “BNC210 Demonstrated Favourable Safety and Tolerability Profile Consistent with Prior Experience” - “Company is Continuing Analysis of the Data and Evaluating Next Steps with Cash Runway into mid-2024” Two weeks ago, the company announced: “Bionomics’ Half-Year Report” for “its FY2023 report for the half-year ended 31 December 2022” As the company explained in this press release: “This period represented a transformational time for Bionomics in which the Company made great strides on multiple fronts, including progress on advancing the pipeline, raising capital, and implementing strategic corporate initiatives designed to create long-term shareholder value.” On Wednesday, the company announced breaking news that could be a positive catalyst: “Bionomics Reports Promising Full Results Analysis from PREVAIL Phase 2 Study of BNC210 Social Anxiety Disorder (SAD)” Here are the highlights: - “Both doses of BNC210 as an acute treatment resulted in reductions in anxiety across multiple phases of the public speaking challenge” - “Results achieved statistical significance in post-hoc analysis of the full data set and in relevant subpopulations” - “Favourable safety, tolerability and PK findings are consistent with a fast-acting non-sedating anxiolytic profile” - “The company is planning an End of Phase 2 (EoPh2) meeting to discuss BNC210’s late-stage SAD program 2H 2023” Here are some of the company’s comments from this press release: “PREVAIL revealed BNC210’s potential as a non-sedating anxiolytic for the acute treatment of SAD. These results follow positive findings in a panic attack model and in patients with generalized anxiety disorder, further support clinical proof of concept in anxiety disorders and de-risk BNC210’s continuing development” remarked Spyros Papapetropoulos MD, PhD, President and Chief Executive Officer of Bionomics. “We look forward to meeting with FDA in the coming months to discuss our clinical path forward for this exciting new therapeutic candidate.” Furthermore: “The full analysis of the data indicates that patients receiving BNC210 show reduced distress compared to placebo. Given the observed effect size in PREVAIL, there is reason to believe that a subsequent trial with a larger sample size could achieve its primary endpoint,” commented Dr. Murray Stein, MD, MPH. Dr. Stein continued “The finding that a statistically significant separation from the placebo occurred when the two dose levels and the anticipation and performance phases were combined is important. Both anticipation and performance are very relevant to understand clinically, so there would be a lot of value in combining these phases as a key data output in future trials.” BNOX could be in a position to experience increased growth. Make sure to do your own due diligence. Sources: [ADAA]( [ADAA2]( [NIH]( [MHA]( [PR1]( [PR2]( [PR3]( [PR4]( [PR5]( [PR6]( [Website]( [Chart]( Happy Trading! AwesomeStocks Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose. DISCLAIMER You should read and understand this disclaimer in its entirety before joining the website or email/blog list of AwesomeStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help. The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete. The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete. Owners and operators of the Publisher have been compensated twelve thousand five hundred dollars by bank wire transfer on 3/8/23 for the distribution of this advertisement about BNOX dated 3/10/23. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time. You are receiving this report/release because you subscribed to receive it at our website or through a third-party site. All our newsletters include an "unsubscribe" link, and you can remove yourself at any time from our newsletters by clicking on that "unsubscribe" link. You can also contact us at info@AwesomeStocks.com to change your information at any time. By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: www.AwesomeStocks.com/Disclaimer and www.AwesomeStocks.com/Privacy-Policy By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink. Our records indicate that {EMAIL} requested and confirmed to be added to AwesomeStocks.com on March 5, 2023. [Click Here To Unsubscribe]( 6020 Bent Pine Dr Orlando Florida 32822 USA [Unsubscribe]( | [Change Subscriber Options](